Medical management of primary aldosteronism

J. Connell

doi:10.1016/j.ando.2009.02.013

Medical management of primary aldosteronism

J. Connell

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	177-178
Number of pages	2
Journal	Annales d'Endocrinologie
Volume	70
Issue number	3
DOIs	https://doi.org/10.1016/j.ando.2009.02.013
Publication status	Published - 2009

Keywords

aldosterone
amiloride
eplerenone
spironolactone
absence of side effects
adenoma
article
biochemistry
cardiovascular disease
drug megadose
genetic variability
genetics
gynecomastia
hormone synthesis
human
hypertension
libido disorder
primary hyperaldosteronism
renin angiotensin aldosterone system
screening
Adenoma
Adrenal Gland Neoplasms
Aldosterone
Humans
Hyperaldosteronism
Hypertension
Renin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ando.2009.02.013

Cite this

@article{69c583c8396a4e479b85c7fbcb67503d,

title = "Medical management of primary aldosteronism",

keywords = "aldosterone, amiloride, eplerenone, spironolactone, absence of side effects, adenoma, article, biochemistry, cardiovascular disease, drug megadose, genetic variability, genetics, gynecomastia, hormone synthesis, human, hypertension, libido disorder, primary hyperaldosteronism, renin angiotensin aldosterone system, screening, Adenoma, Adrenal Gland Neoplasms, Aldosterone, Humans, Hyperaldosteronism, Hypertension, Renin",

author = "J. Connell",

note = "Export Date: 19 March 2012 Source: Scopus CODEN: ANENA doi: 10.1016/j.ando.2009.02.013 PubMed ID: 19286154 Language of Original Document: English Correspondence Address: Connell, J.; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, United Kingdom; email: [email protected] Chemicals/CAS: aldosterone, 52-39-1, 6251-69-0; amiloride, 2016-88-8, 2609-46-3; eplerenone, 107724-20-9; spironolactone, 52-01-7; Aldosterone, 52-39-1; Renin, 3.4.23.15 References: Mulatero, P., Stowasser, M., Loh, K.C., Fardella, C.E., Gordon, R.D., Mosso, L., Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents (2004) J Clin Endocrinol Metab, 89, pp. 1045-1050; Young Jr., W.F., Minireview: primary aldosteronism-changing concepts in diagnosis and treatment (2003) Endocrinology, 144, pp. 2208-2213; Mulatero, P., Rabbia, F., Milan, A., Paglieri, C., Morello, F., Chiandussi, L., Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism (2002) Hypertension, 40, pp. 897-902; Newton-Cheh, C., Guo, C.Y., Gona, P., Larson, M.G., Benjamin, E.J., Wang, T.J., Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample (2007) Hypertension, 49, pp. 846-856; Funder, J.W., Carey, R.M., Fardella, C., Gomez-Sanchez, C.E., Mantero, F., Stowasser, M., Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline (2008) J Clin Endocrinol Metab, 93, pp. 3266-3281; Rossi, G.P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients (2006) J Am Coll Cardiol, 48, pp. 2293-2300; Barr, M., MacKenzie, S.M., Friel, E.C., Holloway, C.D., Wilkinson, D.M., Brain, N.J.R., Polymorphic variation in the 11 beta-hydroxylase gene associates with reduced 11-hydroxylase efficiency (2007) Hypertension, 49, pp. 113-119; Connell, J.M., MacKenzie, S.M., Freel, E.M., Fraser, R., Davies, E., A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function (2008) Endocr Rev",

year = "2009",

doi = "10.1016/j.ando.2009.02.013",

language = "English",

volume = "70",

pages = "177--178",

journal = "Annales d'Endocrinologie",

issn = "0003-4266",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Medical management of primary aldosteronism

AU - Connell, J.

N1 - Export Date: 19 March 2012 Source: Scopus CODEN: ANENA doi: 10.1016/j.ando.2009.02.013 PubMed ID: 19286154 Language of Original Document: English Correspondence Address: Connell, J.; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, United Kingdom; email: [email protected] Chemicals/CAS: aldosterone, 52-39-1, 6251-69-0; amiloride, 2016-88-8, 2609-46-3; eplerenone, 107724-20-9; spironolactone, 52-01-7; Aldosterone, 52-39-1; Renin, 3.4.23.15 References: Mulatero, P., Stowasser, M., Loh, K.C., Fardella, C.E., Gordon, R.D., Mosso, L., Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents (2004) J Clin Endocrinol Metab, 89, pp. 1045-1050; Young Jr., W.F., Minireview: primary aldosteronism-changing concepts in diagnosis and treatment (2003) Endocrinology, 144, pp. 2208-2213; Mulatero, P., Rabbia, F., Milan, A., Paglieri, C., Morello, F., Chiandussi, L., Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism (2002) Hypertension, 40, pp. 897-902; Newton-Cheh, C., Guo, C.Y., Gona, P., Larson, M.G., Benjamin, E.J., Wang, T.J., Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample (2007) Hypertension, 49, pp. 846-856; Funder, J.W., Carey, R.M., Fardella, C., Gomez-Sanchez, C.E., Mantero, F., Stowasser, M., Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline (2008) J Clin Endocrinol Metab, 93, pp. 3266-3281; Rossi, G.P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients (2006) J Am Coll Cardiol, 48, pp. 2293-2300; Barr, M., MacKenzie, S.M., Friel, E.C., Holloway, C.D., Wilkinson, D.M., Brain, N.J.R., Polymorphic variation in the 11 beta-hydroxylase gene associates with reduced 11-hydroxylase efficiency (2007) Hypertension, 49, pp. 113-119; Connell, J.M., MacKenzie, S.M., Freel, E.M., Fraser, R., Davies, E., A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function (2008) Endocr Rev

PY - 2009

Y1 - 2009

KW - aldosterone

KW - amiloride

KW - eplerenone

KW - spironolactone

KW - absence of side effects

KW - adenoma

KW - article

KW - biochemistry

KW - cardiovascular disease

KW - drug megadose

KW - genetic variability

KW - genetics

KW - gynecomastia

KW - hormone synthesis

KW - human

KW - hypertension

KW - libido disorder

KW - primary hyperaldosteronism

KW - renin angiotensin aldosterone system

KW - screening

KW - Adenoma

KW - Adrenal Gland Neoplasms

KW - Aldosterone

KW - Humans

KW - Hyperaldosteronism

KW - Hypertension

KW - Renin

U2 - 10.1016/j.ando.2009.02.013

DO - 10.1016/j.ando.2009.02.013

M3 - Article

SN - 0003-4266

VL - 70

SP - 177

EP - 178

JO - Annales d'Endocrinologie

JF - Annales d'Endocrinologie

IS - 3

ER -